Chronic Pain Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 229 studies associated with Chronic Pain.
Here is a small sampling of Chronic Pain studies by title:
- Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in chronic pain patients
- A Survey on the Effect That Medical Cannabis Has on Prescription Opioid Medication Usage for the Treatment of Chronic Pain at Three Medical Cannabis Practice Sites
- Mixed methods study of the potential therapeutic benefits from medical cannabis for patients in Florida
- Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control
- Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies
Components of the Chronic Pain Research Dashboard
- Dosing information available for Chronic Pain
- Chemotype guidance for treating Chronic Pain with cannabis
- Synopsis of cannabis research for Chronic Pain
- Individual study details for Chronic Pain
Ready to become a subscriber? Go to our PRICING page.
Select New Condition
Search By Keyword
Overview - Chronic Pain
Description of Chronic Pain
The word chronic has its origin in the Greek khronos, meaning time. Chronic pain is usually considered to last more than twelve weeks and is generally less intense than acute pain. Chronic non-malignant pain meet these criteria but also excludes pain caused by cancer.Disease Classification
Condition: Chronic PainDisease Family: Chronic Condition
Organ System: Cardiovascular System, Digestive System, Endocrine System, Immune System, Integumentary System, Mental/Emotional System, Muscular System, Nervous System, Reproductive System, Respiratory System, Skeletal System, Urinary System
ICD-10 Chapter: Diseases of the Nervous System
ICD-10 Code: G89.2
Chronic Pain Symptoms:
Pain that last longer than 3 monthsAlso known as:
Chronic Pain syndromeDrug Interactions
THC Interaction with Pharmaceutical Drugs
- THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example.
- THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), or beta-blockers (propranolol, theophylline, warfarin). Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
- Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
CBD Interaction with Pharmaceutical Drugs
- CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
- Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD
Dosing Considerations
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg (0.001mg/kg to 0.005mg/kg)
- THC low dose: 0.5 mg to 5 mg (0.006mg/kg to 0.06mg/kg)
- THC medium dose: 6 mg to 20 mg (0.08mg/kg to 0.27mg/kg)
- THC high dose: 21 mg to 50+ mg (0.28mg/kg to 0.67mg/kg)
(sample conversion calculated on a person weighing 75kg)
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg (0.005mg/kg to 0.25mg/kg)
- CBD medium dose: 20 mg to 99 mg (0.26mg/kg to 1.32mg/kg)
- CBD high dose: 100 mg to 800+ mg (1.33mg/kg to 10.7mg/kg)
- (upper limits tested ~1,500mg)
(sample conversion calculated on a person weighing 75kg)
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.